The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Saved in:
| Title: | The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. |
|---|---|
| Authors: | Nachman S (AUTHOR), Gona P (AUTHOR), Dankner W (AUTHOR), Weinberg A (AUTHOR), Yogev R (AUTHOR), Gershon A (AUTHOR), Rathore M (AUTHOR), Read JS (AUTHOR), Huang S (AUTHOR), Elgie C (AUTHOR), Hudgens K (AUTHOR), Hughes W (AUTHOR) |
| Source: | Pediatrics. 2005 Apr Supplement, Vol. 115 Issue 4 Part 1, pe488-94. 1p. |
| Abstract: | Objective. Receipt of highly active antiretroviral therapy is associated with a decrease in the incidence of opportunistic infections (OIs) among HIV-infected adults. The goal of Pediatric AIDS Clinical Trials Group protocol 1008 was to evaluate prospectively the incidence of serious bacterial infections (SBIs) and other OIs after discontinuation of OI and/or Pneumocystis jiroveci pneumonia (PCP) prophylaxis among HIV-infected pediatric subjects who experienced immune reconstitution while receiving stable antiretroviral therapy.Methods. HIV-infected children and adolescents, 2 to 21 years of age, who had received OI and/or PCP prophylaxis for 6 months were enrolled if they had sustained responses (>16 weeks before study entry) to antiretroviral therapy, with CD4+ cell percentages of 20% for patients >6 years of age or 25% for patients 2 to 6 years of age. Prophylaxis was discontinued at entry. To identify whether any correlation existed between functional immune reconstitution and protection from OIs, subjects were immunized with the hepatitis A virus vaccine. The association between the humoral immune response and the likelihood of developing an OI was evaluated.Results. A total of 235 HIV-infected subjects from 43 participating sites had a median follow-up period of 132 weeks, yielding 547 person-years of observation. Twenty SBIs were observed among 19 subjects, resulting in an incidence rate of 3.66 SBIs per 100 person-years (95% confidence interval: 2.24-5.66 SBIs per 100 person-years). Sixteen of the events were presumed bacterial pneumonia, with 4 proven SBIs. One participant experienced 2 separate pneumonia episodes, of presumed bacterial cause. Ten subjects who developed SBIs had baseline CD4+ cell counts of 750 cells per mm[3], and 15 had CD4+ cell percentages of 25% at the time of their SBIs. Two subjects died as a result of non-SBI-related causes. There were no statistically significant differences in changes over time in CD4+ cell counts or CD4+ cell percentages between subjects who experienced primary end points and those who did not. There was no evidence that baseline protease inhibitor use, gender, race/ethnicity, age, or CD4+ cell count or percentage affected the time to development of a SBI.Conclusions. OI or PCP prophylaxis can be withdrawn safely for HIV-infected pediatric patients who experience CD4+ cell recovery while receiving stable antiretroviral therapy. More studies are needed to assess the association between antibody responses to neoantigens and the development of SBIs. [ABSTRACT FROM AUTHOR] |
| Copyright of Pediatrics is the property of American Academy of Pediatrics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 106488919 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Nachman+S%22">Nachman S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gona+P%22">Gona P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dankner+W%22">Dankner W</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weinberg+A%22">Weinberg A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yogev+R%22">Yogev R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gershon+A%22">Gershon A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rathore+M%22">Rathore M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Read+JS%22">Read JS</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Huang+S%22">Huang S</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Elgie+C%22">Elgie C</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hudgens+K%22">Hudgens K</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hughes+W%22">Hughes W</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Pediatrics%22">Pediatrics</searchLink>. 2005 Apr Supplement, Vol. 115 Issue 4 Part 1, pe488-94. 1p. – Name: Abstract Label: Abstract Group: Ab Data: Objective. Receipt of highly active antiretroviral therapy is associated with a decrease in the incidence of opportunistic infections (OIs) among HIV-infected adults. The goal of Pediatric AIDS Clinical Trials Group protocol 1008 was to evaluate prospectively the incidence of serious bacterial infections (SBIs) and other OIs after discontinuation of OI and/or Pneumocystis jiroveci pneumonia (PCP) prophylaxis among HIV-infected pediatric subjects who experienced immune reconstitution while receiving stable antiretroviral therapy.Methods. HIV-infected children and adolescents, 2 to 21 years of age, who had received OI and/or PCP prophylaxis for 6 months were enrolled if they had sustained responses (>16 weeks before study entry) to antiretroviral therapy, with CD4+ cell percentages of 20% for patients >6 years of age or 25% for patients 2 to 6 years of age. Prophylaxis was discontinued at entry. To identify whether any correlation existed between functional immune reconstitution and protection from OIs, subjects were immunized with the hepatitis A virus vaccine. The association between the humoral immune response and the likelihood of developing an OI was evaluated.Results. A total of 235 HIV-infected subjects from 43 participating sites had a median follow-up period of 132 weeks, yielding 547 person-years of observation. Twenty SBIs were observed among 19 subjects, resulting in an incidence rate of 3.66 SBIs per 100 person-years (95% confidence interval: 2.24-5.66 SBIs per 100 person-years). Sixteen of the events were presumed bacterial pneumonia, with 4 proven SBIs. One participant experienced 2 separate pneumonia episodes, of presumed bacterial cause. Ten subjects who developed SBIs had baseline CD4+ cell counts of 750 cells per mm[3], and 15 had CD4+ cell percentages of 25% at the time of their SBIs. Two subjects died as a result of non-SBI-related causes. There were no statistically significant differences in changes over time in CD4+ cell counts or CD4+ cell percentages between subjects who experienced primary end points and those who did not. There was no evidence that baseline protease inhibitor use, gender, race/ethnicity, age, or CD4+ cell count or percentage affected the time to development of a SBI.Conclusions. OI or PCP prophylaxis can be withdrawn safely for HIV-infected pediatric patients who experience CD4+ cell recovery while receiving stable antiretroviral therapy. More studies are needed to assess the association between antibody responses to neoantigens and the development of SBIs. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Pediatrics is the property of American Academy of Pediatrics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=106488919 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1542/peds.2004-1847 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: e488 Titles: – TitleFull: The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Nachman S – PersonEntity: Name: NameFull: Gona P – PersonEntity: Name: NameFull: Dankner W – PersonEntity: Name: NameFull: Weinberg A – PersonEntity: Name: NameFull: Yogev R – PersonEntity: Name: NameFull: Gershon A – PersonEntity: Name: NameFull: Rathore M – PersonEntity: Name: NameFull: Read JS – PersonEntity: Name: NameFull: Huang S – PersonEntity: Name: NameFull: Elgie C – PersonEntity: Name: NameFull: Hudgens K – PersonEntity: Name: NameFull: Hughes W IsPartOfRelationships: – BibEntity: Dates: – D: 03 M: 04 Text: 2005 Apr Supplement Type: published Y: 2005 Identifiers: – Type: issn-print Value: 00314005 Numbering: – Type: volume Value: 115 – Type: issue Value: 4 Part 1 Titles: – TitleFull: Pediatrics Type: main |
| ResultId | 1 |
